The project is to explore in humans the hypothesis of the link between the alteration of tubulo-interstitial metabolism and the rate of deterioration of renal function by comparing various nephropathies.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Spatial lipidomics for measuring tubular dysmetabolism
Timeframe: Through study completion up to end of study, when the last patients completed 1 year follow-up.
Co-staining for measuring tubular segments markers
Timeframe: Through study completion up to end of study, when the last patients completed 1 year follow-up
Immunofluorescence (at the protein level) for measuring peroxisome Proliferator-Activated Receptor-Gamma (PPAR-gamma)
Timeframe: Through study completion up to end of study, when the last patients completed 1 year follow-up
Spatial transcriptomics (at the mRNA level) for measuring peroxisome Proliferator-Activated Receptor-Gamma (PPAR-gamma)
Timeframe: Through study completion up to end of study, when the last patients completed 1 year follow-up